POTENSI CONOTOXIN DARI CONUS SPESIES SEBAGAI ANALGESIK

Authors

  • Izzatiana Nabila Ramadhani Universitas Hang Tuah Surabaya- Fakultas Kedokteran. Program Studi Farmasi
  • Nani Wijayanti D. N. Program Studi Farmasi Universitas Hang Tuah
  • Giftania Wardhani Sudjarwo Program Studi Farmasi Universitas Hang Tuah

DOI:

https://doi.org/10.30649/pst.v3i2.46

Keywords:

pain, analgesic, ziconotide, conotoxin, conus

Abstract

Pain is an unpleasant sensory and emotional experience resulting from actual or potential tissue damage or tends to damage tissue. Analgesic is one of the therapies commonly used to relieve pain. Analgesic itself is divided into two types, namely opioids and non-opioid, where each of these drugs has effectiveness and side effects. Researchers are trying to find other alternatives that have the potential as analgesics, with high effectiveness and fewer side effects. Conotoxin is a venom derived from Conus and it has potential as an analgesic. One form of Conotoxin that has been developed is Ziconotide. Ziconotide works by activating miu receptors that block N-type calcium channels through the G protein mechanism so that the transmission of pain signals to nerve cells can be inhibited at the spinal cord level. This review article aims to evaluate the use of Ziconotide as an analgesic. The evaluation was carried out by considering the effectiveness and the emergence of side effects from 10 article related to Ziconotide based on inclusion and exclusion criteria. The results obtained from this review article are that Ziconotide has a fairly high effectiveness as an analgesic, this can be proven by the number of patients experiencing pain reduction of more than 30% at least 40% of the population in each literature, as well as side effects that can be said to be quite mild.

Downloads

Download data is not yet available.

References

Anggraika P, Apriani A, Pujianan D. (2019). Hubungan Posisi Duduk Dengan Kejadian Low Back Pain Pada Pegawai Stikes. Jurnal'Aisyiyah Medika. Vol. 4(1).

Alicino, I., Giglio, M., Manca, F., Bruno, F., & Puntillo, F. (2012). Intrathecal combination of ziconotide and morphine for refractory cancer pain: a rapidly acting and effective choice. Pain, 153(1), 245- 249.

Bäckryd, E., Sörensen, J., & Gerdle, B. (2015). Ziconotide trialing by intrathecal bolus injections: an open-label non- randomized clinical trial in postoperative/posttraumatic neuropathic pain patients refractory to conventional treatment. Neuromodulation: Technology at the Neural Interface, 18(5), 404-413.

Cappello, Emiliano & Nieri, Paola. (2021). From Life in the Sea to the Clinic: The Marine Drugs Approved and under Clinical Trial. Life. 11. 1390.

Chalil, A., Staudt, M. D., Harland, T. A., Leimer, E. M., Bhullar, R., & Argoff, C. E. (2021). A safety review of approved Intrathecal analgesics for chronic pain management. Expert opinion on drug safety, 20(4), 439-451.

Chandra, C., Tjitrosantoso, H., dan Lolo,

W. A. (2016). Studi Penggunaan Obat Analgesik pada Pasien Cedera Kepala (Concussion) di RSUP Prof. Dr. RD Kandou Manado Periode Januari- Desember 2014. PHARMACON, 5(2).

Deer, T., Rauck, R. L., Kim, P., Saulino,

M. F., Wallace, M., Grigsby, E. J., ... & McDowell, G. C. (2018). Effectiveness and safety of Intrathecal ziconotide: Interim analysis of the Patient Registry of Intrathecal Ziconotide Management (PRIZM). Pain Practice, 18(2), 230-238.

Dupoiron, D., Bore, F., Lefebvre-Kuntz, D., Brenet, O., de Bourmont, S., Dixmerias, F., ... & Monnin, D. (2012). Ziconotide adverse events in patients with cancer pain: a multicenter observational study of a slow titration, multidrug protocol. Pain physician, 15(5), 395.

Gregory, A. T., & Denniss, A. R. (2018). An introduction to writing narrative and systematic reviews—Tasks, tips and traps for aspiring authors. Heart, Lung and Circulation, 27(7), 893-898.

Gunawan, Y. (2010). Perbandingan efek anal genetika kombinasi blok paraservikal dan asam mefenamat dengan kombinasi blok paraservikal pada tindakan kuretase (Doctoral dissertation, Universitas Gadjah Mada).

Kumbea, N. P., Sumampouw, O. J., & Asrifuddin, A. (2021). Keluhan Nyeri Punggung Bawah Pada Nelayan. Indonesian Journal of Public Health and Community Medicine, 2(1), 021-026

Kumari, A., Ameri, S., Marraiki, N., Elgorban, A. M., Aroulmoji, V., Ponnuchamy, K., … Selvankumar, T. (2020). Isolation, Characterization and In- Silico Study of Conotoxin Protein from Conus loroisii and Its Anti-cancer Activity. International Journal of Peptide Research and Therapeutics.

Lindley, D. (2021). Short-Term Outcomes of a High-Volume, Low-Concentration Bolus Starting Dose Technique With Ziconotide: A Case Series. Neuromodulation: Technology at the Neural Interface, 24(7), 1209-1214.

McDowell II, G. C., & Pope, J. E. (2016). Intrathecal Ziconotideee: dosing and administration strategies in patients with refractory chronic pain. Neuromodulation: Technology at the Neural Interface, 19(5), 522-532.

Mohammed, S. I., Eldabe, S., Simpson, K. H., Brookes, M., Madzinga, G., Gulve, A.,

... & Batterham, A. M. (2013). Bolus Intrathecal injection of ziconotide (Prialt®) to evaluate the option of continuous administration via an implanted Intrathecal drug delivery (ITDD) system: a pilot study. Neuromodulation: Technology at the Neural Interface, 16(6), 576-582.

Prusik, J., Argoff, C., Peng, S., & Pilitsis,

J. G. (2017). Use of low dose ziconotide as first-line Intrathecal monotherapy. Neuromodulation: Technology at the Neural Interface, 20(4), 386-391.

Raffaeli, W., Sarti, D., Demartini, L., Sotgiu, A., & Bonezzi, C. (2011). Italian registry on long-term Intrathecal ziconotide treatment. Pain Physician, 14(1), 15.

Rauck, R. L., Wallace, M. S., Leong, M. S., MineHart, M., Webster, L. R., Charapata, S. G., ... & Ziconotide 301 Study Group. (2006). A randomized, double-blind, placebo-controlled study of Intrathecal Ziconotide in adults with severe chronic pain. Journal of pain and symptom management, 31(5), 393-406.

Schug, S. A., Palmer, G. M., Scott, D. A., Alcock, M., Halliwell, R., & Mott, J. (Eds.). (2020). Acute pain management: scientific evidence. Australian and New Zealand College of Anaesthetists.

Safavi-Hemami, H., Brogan, S. E., & Olivera, B. M. (2019). Pain therapeutics from cone snail venoms: From Ziconotideee to novel non-opioid pathways. Journal of proteomics, 190, 12- 20.

Sinol, H. A., Parekh, A. N., Gohil, J. R., & Gosai, M. (2020). Paracetamol vs ibuprofen in hemodynamically significant patent ductus arteriosus (HsPDA) in preterms: a randomized controlled trial. Asian J Pediatr Res, 3(1), 6-13.

Sipahutar, L. R. B., Ompusunggu, H. E. S., & Napitupulu, R. R. J. (2021). Gambaran Penggunaan Obat Analgetik secara Rasional dalam Swamedikasi pada Masyarakat PKS Balam, Desa Balai Jaya Km. 31 Kecamatan Balam Sempurna, Kabupaten Rokan Hilir, Riau. Nommensen Journal of Medicine, 6(2), 53-57

Staub, B. P., Casini, G. P., Monaco III, E. A., Sekula Jr, R. F., & Emerick, T. D. (2019). Near-resolution of persistent idiopathic facial pain with low-dose lumbar Intrathecal ziconotide: a case report.

Journal of Pain Research, 12, 94

Tucker, J. K., & Tenorio, M. J. (2013). Illustrated catalog of living cone shell

Downloads

Published

2022-12-20

How to Cite

Ramadhani, I. N., Nurrahman, N. W. D. ., & Sudjarwo, G. W. . (2022). POTENSI CONOTOXIN DARI CONUS SPESIES SEBAGAI ANALGESIK. JOURNAL OF PHARMACY SCIENCE AND TECHNOLOGY, 3(2), 70–81. https://doi.org/10.30649/pst.v3i2.46

Issue

Section

Articles